Bayer is studying an investigational drug, Vilaprasin, in women who have been diagnosed with uterine fibroids, to treat heavy menstrual bleeding. Subjects will take an oral medication or placebo. Subjects will remain in the study for about 16 months and involves up to 8 visits.
The primary investigators/residents have noted during clinical rotations that a significant number of GBS unknown mothers at SRHS are being treated with intrapartum antibiotics even without the presence of risk factors, presumably to decrease postpartum/neonatal length of stay.
Our study, a retrospective chart review, will determine whether or not length of stay is affected by treating GBS unknown mothers with intrapartum antibiotics in the absence of the aforementioned risk factors.
Potential benefits include the cost-effectiveness of decreased length of stay for these patients as well as decreased exposure to nosocomial infections for neonates. However, antibiotic stewardship and patient safety are also considerations. Another potential option for these patients is rapid GBS testing with PCR which can provide results in 1-2 hours compared with 24-48 hours for the standard culture. PCR is not currently available at SMC.
Bayer is studying an investigational drug, Vilaprasin, in women who have been diagnosed with uterine fibroids vs standard treatment.
This study will compare 0.1mg and 0.05mg of spinal morphine for postoperative pain after scheduled, elective Cesarean delivery. All patients will receive a spinal anesthetic (single injection in the lower back to numb patients from the waist down) for operative anesthesia and will be
randomized into one of two groups: (group 1) 0.1mg spinal morphine and (group 2) 0.05mg spinal morphine. This will be a randomized, single blinded study.
This study is try to understand current patients with fibroids and there choices for management. We will follow women through their journey and obtain patient reported outcomes, through questionnaire's, following their current therapies for Uterine Fibroids, including symptoms, quality of life, work productivity impact, and satisfaction.
The purpose of this study is to evaluate the safety and benefits of treating mild chronic hypertension (CHTN), or high blood pressure, with medication during pregnancy vs non treatment. Medication prescribed is medication currently approved to treat severe CHTN.
The purpose of this study is to validate a test developed to determine preterm labor, to determine the optimal time to preform the test, and to discover biomarkers that will date a pregnancy and predict the time to birth.
The purpose of this study is to study an alternative to unopposed estrogen in premenopausal women that have endometriosis-related pain at the time of hysterectomy (removal of the womb). We will compare a type of estrogen alone with another combination medication that has the same type of estrgrogen plus another medication called bazodoxiphene (Duavee). We will compare the effect of Duavee with estrogen alone on endometriosis-associated pain scores after 6 months of therapy.
Women who have completed treatment for stage II, III or IV ovarian, fallopian tube or primary peritoneal cancer and are cancer free will be randomized to either Group 1 (diet and physical activity intervention group) or Group 2 (the usual diet and physical activity group). Group 1 Intervention will include regularly scheduled lifestyle intervention coaching sessions that will be conducted over the telephone and increased physical activity. Patients will be asked to complete daily lifestyle journal that will track daily fat grams and steps. Group 2 will continue with ususal diet and physical activity and will participate in coaching phone calls. Participants will be asked to complete Patient Questionnaires. If participants consent to optional blood submission study, blood samples for research will be drawn at baseline, 3, 6,12 and 24 months from study entry. Participation will last for 24 months.
This study will evaluate a remote patient monitoring solution for low-risk pregnancies to assess whether or not it produces equivalent care with regards to clinical outcomes and patient satisfaction at a lower cost to the healthcare system and its participants. Furthermore, we will measure the ability of participants to collect and record the necessary data.